Knowns and unknowns of influenza B viruses

References

• 1 Francis T Jr. A new type of virus from epidemic influenza. Science 92(2392), 405–408 (1940).
  MedlineGoogle Scholar
• 2 Jackson D, Elderfield RA, Barclay WS. Molecular studies of influenza B virus in the reverse genetics era. J. Gen. Virol. 92(Pt 1), 1–17 (2011).
  Medline CASGoogle Scholar
• 3 Peter Palese MLS. Orthomyxoviridae: the viruses and their replication. In: Fields Virology. Knipe DM (Ed.). Lippincott Williams & Wilkins, PA, USA (2007).
  Google Scholar
• 4 Krumbholz A, Philipps A, Oehring H et al. Current knowledge on PB1-F2 of influenza A viruses. Med. Microbiol. Immunol. 200(2), 69–75 (2011).
  Medline CASGoogle Scholar
• 5 Shi M, Jagger BW, Wise HM, Digard P, Holmes EC, Taubenberger JK. Evolutionary conservation of the PA-X open reading frame in segment 3 of influenza A virus. J. Virol. 86(22), 12411–12413 (2012).
  Medline CASGoogle Scholar
• 6 Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175(1), 59–68 (1990).
  Medline CASGoogle Scholar
• 7 McCullers JA, Saito T, Iverson AR. Multiple genotypes of influenza B virus circulated between 1979 and 2003. J. Virol. 78(23), 12817–12828 (2004).
  Medline CASGoogle Scholar
• 8 Vijaykrishna D, Holmes EC, Joseph U et al. The contrasting phylodynamics of human influenza B viruses. eLife 4, e05055 (2015).
  MedlineGoogle Scholar
• 9 Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179–186 (2003).
  MedlineGoogle Scholar
• 10 Lin YP, Gregory V, Bennett M, Hay A. Recent changes among human influenza viruses. Virus Res. 103(1–2), 47–52 (2004).
  Medline CASGoogle Scholar
• 11 Paul Glezen W, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. The burden of influenza B: a structured literature review. Am. J. Public Health 103(3), e43–e51 (2013).
  Medline CASGoogle Scholar
• 12 Gutierrez-Pizarraya A, Perez-Romero P, Alvarez R et al. Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave. J. Infect. 65(5), 423–430 (2012).
  Medline CASGoogle Scholar
• 13 Su S, Chaves SS, Perez A et al. Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection. Clin. Infect. Dis. 59(2), 252–255 (2014).
  Medline CASGoogle Scholar
• 14 Thompson WW, Moore MR, Weintraub E et al. Estimating influenza-associated deaths in the United States. Am. J. Public Health, 99(Suppl. 2), S225–S230 (2009).
  MedlineGoogle Scholar
• 15 Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of mortality attributable to influenza and RSV in the United States during 1997–2009 by influenza type or subtype, age, cause of death, and risk status. Influenza Other Respir. Viruses 8(5), 507–515 (2014).
  MedlineGoogle Scholar
• 16 Kaczmarek M, Owen R, Barr IG. Annual report of the National Influenza Surveillance Scheme, 2008. Commun. Dis. Intell. Q. Rep. 34(1), 8–22 (2010).
  MedlineGoogle Scholar
• 17 Public Health England. Surveillance of Influenza and Other Respiratory Viruses, including Novel Respiratory Viruses, in the United Kingdom: Winter 2012/13. Public Health England, London, UK (2013).
  Google Scholar
• 18 Tewawong N, Suwannakarn K, Prachayangprecha S et al. Molecular epidemiology and phylogenetic analyses of influenza B virus in Thailand during 2010 to 2014. PLoS ONE 10(1), e0116302 (2015).
  MedlineGoogle Scholar
• 19 Wright PF, Neumann G, Kawaoka Y. Orthomixoviruses. In: Fields Virology. Knipe DM (Ed.). Lippincott Williams & Wilkins, PA, USA (2007).
  Google Scholar
• 20 Irving SA, Patel DC, Kieke BA et al. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004–2005 through 2007–2008. Influenza Other Respir. Viruses 6(1), 37–43 (2012).
  MedlineGoogle Scholar
• 21 Moon JH, Na JY, Kim JH et al. Neurological and muscular manifestations associated with influenza B infection in children. Pediatr. Neurol. 49(2), 97–101 (2013).
  MedlineGoogle Scholar
• 22 Thabet FI, Khalil S, Naz F, Dyme IZ. Cerebellar mutism and reversible cytotoxic edema in influenza B-associated encephalopathy. Pediatr. Neurol. 49(6), 489–492 (2013).
  MedlineGoogle Scholar
• 23 Frank H, Wittekind C, Liebert UG et al. Lethal influenza B myocarditis in a child and review of the literature for pediatric age groups. Infection 38(3), 231–235 (2010).
  Medline CASGoogle Scholar
• 24 Paddock CD, Liu L, Denison AM et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J. Infect. Dis. 205(6), 895–905 (2012).
  MedlineGoogle Scholar
• 25 Taremi M, Amoroso A, Nace HL, Gilliam BL. Influenza B-induced refractory cardiogenic shock: a case report. BMC Infect. Dis. 13, 452 (2013).
  MedlineGoogle Scholar
• 26 Aebi T, Weisser M, Bucher E, Hirsch HH, Marsch S, Siegemund M. Co-infection of influenza B and streptococci causing severe pneumonia and septic shock in healthy women. BMC Infect. Dis. 10, 308 (2010).
  MedlineGoogle Scholar
• 27 Scaber J, Saeed S, Ihekweazu C, Efstratiou A, McCarthy N, O’Moore E. Group A streptococcal infections during the seasonal influenza outbreak 2010/11 in south east England. Euro Surveill. 16(5), pii:19780 (2011).
  MedlineGoogle Scholar
• 28 van der Vries E, Ip DK, Cowling BJ et al. Outcomes and susceptibility to neuraminidase inhibitors in individuals infected with different influenza B lineages: the Influenza Resistance Information Study. J. Infect. Dis. pii: jiv375 (2015) (Epub ahead of print).
  Google Scholar
• 29 Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 28(Suppl. 4), D45–D53 (2010).
  MedlineGoogle Scholar
• 30 Hite LK, Glezen WP, Demmler GJ, Munoz FM. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int. J. Infect. Dis. 11(1), 40–47 (2007).
  MedlineGoogle Scholar
• 31 Olson DR, Heffernan RT, Paladini M, Konty K, Weiss D, Mostashari F. Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City. PLoS Med. 4(8), e247 (2007).
  MedlineGoogle Scholar
• 32 Socan M, Prosenc K, Ucakar V, Berginc N. A comparison of the demographic and clinical characteristics of laboratory-confirmed influenza B Yamagata and Victoria lineage infection. J. Clin. Virol. 61(1), 156–160 (2014).
  MedlineGoogle Scholar
• 33 Tan Y, Guan W, Lam TT et al. Differing epidemiological dynamics of influenza B virus lineages in Guangzhou, southern China, 2009–2010. J. Virol. 87(22), 12447–12456 (2013).
  Medline CASGoogle Scholar
• 34 Wang YF, Chang CF, Chi CY, Wang HC, Wang JR, Su IJ. Characterization of glycan binding specificities of influenza B viruses with correlation with hemagglutinin genotypes and clinical features. J. Med. Virol. 84(4), 679–685 (2012).
  Medline CASGoogle Scholar
• 35 Skowronski DM, Janjua NZ, Sabaiduc S et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011–2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J. Infect. Dis. 210(1), 126–137 (2014).
  Medline CASGoogle Scholar
• 36 Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J. Mol. Evol. 66(6), 655–663 (2008).
  Medline CASGoogle Scholar
• 37 Bedford T, Riley S, Barr IG et al. Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature 523(7559), 217–220 (2015).
  Medline CASGoogle Scholar
• 38 Patterson Ross Z, Komadina N, Deng YM et al. Inter-seasonal influenza is characterized by extended virus transmission and persistence. PLoS Pathog. 11(6), e1004991 (2015).
  MedlineGoogle Scholar
• 39 Nelson MI, Simonsen L, Viboud C et al. Stochastic processes are key determinants of short-term evolution in influenza a virus. PLoS Pathog. 2(12), e125 (2006).
  MedlineGoogle Scholar
• 40 Dudas G, Bedford T, Lycett S, Rambaut A. Reassortment between influenza B lineages and the emergence of a coadapted PB1–PB2–HA gene complex. Mol. Biol. Evol. 32(1), 162–172 (2015).
  Medline CASGoogle Scholar
• 41 Laurie KL, Guarnaccia TA, Carolan LA et al. Interval between infections and viral hierarchy are determinants of viral interference following influenza virus infection in a ferret model. J. Infect. Dis 212(11), 1701–1710 (2015).
  Medline CASGoogle Scholar
• 42 Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier RA. Influenza B virus in seals. Science 288(5468), 1051–1053 (2000).
  Medline CASGoogle Scholar
• 43 Blanc A, Ruchansky D, Clara M, Achaval F, Le Bas A, Arbiza J. Serologic evidence of influenza A and B viruses in South American fur seals (Arctocephalus australis). J. Wildlife Dis. 45(2), 519–521 (2009).
  MedlineGoogle Scholar
• 44 Bodewes R, van de Bildt MW, van Elk CE et al. No serological evidence that harbour porpoises are additional hosts of influenza B viruses. PloS ONE 9(2), e89058 (2014).
  MedlineGoogle Scholar
• 45 Ran Z, Shen H, Lang Y et al. Domestic pigs are susceptible to infection with influenza B viruses. J. Virol. 89(9), 4818–4826 (2015).
  Medline CASGoogle Scholar
• 46 Leyva-Grado VH, Mubareka S, Krammer F, Cardenas WB, Palese P. Influenza virus infection in guinea pigs raised as livestock, Ecuador. Emerg. Infect. Dis. 18(7), 1135–1138 (2012).
  Medline CASGoogle Scholar
• 47 Pica N, Chou YY, Bouvier NM, Palese P. Transmission of influenza B viruses in the guinea pig. J. Virol. 86(8), 4279–4287 (2012).
  Medline CASGoogle Scholar
• 48 Elderfield RA, Parker L, Stilwell P, Roberts KL, Schepelmann S, Barclay WS. Ferret airway epithelial cell cultures support efficient replication of influenza B virus but not mumps virus. J. Gen. Virol. 96(8), 2092–2098 (2015).
  Medline CASGoogle Scholar
• 49 Guan R, Ma LC, Leonard PG et al. Structural basis for the sequence-specific recognition of human ISG15 by the NS1 protein of influenza B virus. Proc. Natl Acad. Sci. USA 108(33), 13468–13473 (2011).
  Medline CASGoogle Scholar
• 50 McCullers JA, Hoffmann E, Huber VC, Nickerson AD. A single amino acid change in the C-terminal domain of the matrix protein M1 of influenza B virus confers mouse adaptation and virulence. Virology 336(2), 318–326 (2005).
  Medline CASGoogle Scholar
• 51 Wang Q, Tian X, Chen X, Ma J. Structural basis for receptor specificity of influenza B virus hemagglutinin. Proc. Natl Acad. Sci. USA 104(43), 16874–16879 (2007).
  Medline CASGoogle Scholar
• 52 Matrosovich MN, Gambaryan AS, Tuzikov AB et al. Probing of the receptor-binding sites of the H1 and H3 influenza A and influenza B virus hemagglutinins by synthetic and natural sialosides. Virology 196(1), 111–121 (1993).
  Medline CASGoogle Scholar
• 53 Wang Q, Cheng F, Lu M, Tian X, Ma J. Crystal structure of unliganded influenza B virus hemagglutinin. J. Virol. 82(6), 3011–3020 (2008).
  Medline CASGoogle Scholar
• 54 Ni F, Mbawuike IN, Kondrashkina E, Wang Q. The roles of hemagglutinin Phe-95 in receptor binding and pathogenicity of influenza B virus. Virology 450–451, 71–83 (2014).
  MedlineGoogle Scholar
• 55 Medina RA, Garcia-Sastre A. Influenza A viruses: new research developments. Nat. Rev. Microbiol. 9(8), 590–603 (2011).
  Medline CASGoogle Scholar
• 56 Burmeister WP, Ruigrok RW, Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11(1), 49–56 (1992).
  Medline CASGoogle Scholar
• 57 Burnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res. 100(2), 520–534 (2013).
  Medline CASGoogle Scholar
• 58 Williams MA, Lamb RA. Effect of mutations and deletions in a bicistronic mRNA on the synthesis of influenza B virus NB and NA glycoproteins. J. Virol. 63(1), 28–35 (1989).
  Medline CASGoogle Scholar
• 59 Betakova T, Nermut MV, Hay AJ. The NB protein is an integral component of the membrane of influenza B virus. J. Gen. Virol. 77(Pt 11), 2689–2694 (1996).
  Medline CASGoogle Scholar
• 60 Williams MA, Lamb RA. Polylactosaminoglycan modification of a small integral membrane glycoprotein, influenza B virus NB. Mol. Cell. Biol. 8(3), 1186–1196 (1988).
  Medline CASGoogle Scholar
• 61 Demers A, Ran Z, Deng Q et al. Palmitoylation is required for intracellular trafficking of influenza B virus NB protein and efficient influenza B virus growth in vitro. J. Gen. Virol. 95(Pt 6), 1211–1220 (2014).
  Medline CASGoogle Scholar
• 62 Hatta M, Kawaoka Y. The NB protein of influenza B virus is not necessary for virus replication in vitro. J. Virol. 77(10), 6050–6054 (2003).
  Medline CASGoogle Scholar
• 63 Shimbo K, Brassard DL, Lamb RA, Pinto LH. Viral and cellular small integral membrane proteins can modify ion channels endogenous to xenopus oocytes. Biophys. J. 69(5), 1819–1829 (1995).
  Medline CASGoogle Scholar
• 64 Ewart GD, Sutherland T, Gage PW, Cox GB. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J. Virol. 70(10), 7108–7115 (1996).
  Medline CASGoogle Scholar
• 65 Sunstrom NA, Premkumar LS, Premkumar A, Ewart G, Cox GB, Gage PW. Ion channels formed by NB, an influenza B virus protein. J. Membr. Biol. 150(2), 127–132 (1996).
  Medline CASGoogle Scholar
• 66 Fischer WB, Pitkeathly M, Wallace BA, Forrest LR, Smith GR, Sansom MS. Transmembrane peptide NB of influenza B: a simulation, structure, and conductance study. Biochemistry 39(41), 12708–12716 (2000).
  Medline CASGoogle Scholar
• 67 Lamb RA, Pinto LH. Do Vpu and Vpr of human immunodeficiency virus type 1 and NB of influenza B virus have ion channel activities in the viral life cycles? Virology 229(1), 1–11 (1997).
  Medline CASGoogle Scholar
• 68 Betakova T, Hay AJ. Evidence that the CM2 protein of influenza C virus can modify the pH of the exocytic pathway of transfected cells. J. Gen. Virol. 88(Pt 8), 2291–2296 (2007).
  Medline CASGoogle Scholar
• 69 Cao S, Jiang J, Li J et al. Characterization of the nucleocytoplasmic shuttle of the matrix protein of influenza B virus. J. Virol. 88(13), 7464–7473 (2014).
  MedlineGoogle Scholar
• 70 Briedis DJ, Lamb RA, Choppin PW. Sequence of RNA segment 7 of the influenza B virus genome: partial amino acid homology between the membrane proteins (M1) of influenza A and B viruses and conservation of a second open reading frame. Virology 116(2), 581–588 (1982).
  Medline CASGoogle Scholar
• 71 Paterson RG, Takeda M, Ohigashi Y, Pinto LH, Lamb RA. Influenza B virus BM2 protein is an oligomeric integral membrane protein expressed at the cell surface. Virology 306(1), 7–17 (2003).
  Medline CASGoogle Scholar
• 72 Odagiri T, Hong J, Ohara Y. The BM2 protein of influenza B virus is synthesized in the late phase of infection and incorporated into virions as a subviral component. J. Gen. Virol. 80(Pt 10), 2573–2581 (1999).
  Medline CASGoogle Scholar
• 73 Watanabe S, Imai M, Ohara Y, Odagiri T. Influenza B virus BM2 protein is transported through the trans-Golgi Network as an integral membrane protein. J. Virol. 77(19), 10630–10637 (2003).
  Medline CASGoogle Scholar
• 74 Wang J, Pielak RM, McClintock MA, Chou JJ. Solution structure and functional analysis of the influenza B proton channel. Nat. Struct. Mol. Biol. 16(12), 1267–1271 (2009).
  Medline CASGoogle Scholar
• 75 Imai M, Watanabe S, Ninomiya A, Obuchi M, Odagiri T. Influenza B virus BM2 protein is a crucial component for incorporation of viral ribonucleoprotein complex into virions during virus assembly. J. Virol. 78(20), 11007–11015 (2004).
  Medline CASGoogle Scholar
• 76 Jackson D, Zurcher T, Barclay W. Reduced incorporation of the influenza B virus BM2 protein in virus particles decreases infectivity. Virology 322(2), 276–285 (2004).
  Medline CASGoogle Scholar
• 77 Hatta M, Goto H, Kawaoka Y. Influenza B virus requires BM2 protein for replication. J. Virol. 78(11), 5576–5583 (2004).
  Medline CASGoogle Scholar
• 78 Mould JA, Paterson RG, Takeda M et al. Influenza B virus BM2 protein has ion channel activity that conducts protons across membranes. Dev. Cell 5(1), 175–184 (2003).
  Medline CASGoogle Scholar
• 79 Ma C, Soto CS, Ohigashi Y et al. Identification of the pore-lining residues of the BM2 ion channel protein of influenza B virus. J. Biol. Chem. 283(23), 15921–15931 (2008).
  Medline CASGoogle Scholar
• 80 Zhang H, Yu H, Wang J et al. The BM2 protein of influenza B virus interacts with p53 and inhibits its transcriptional and apoptotic activities. Mol. Cell. Biochem. 403(1–2), 187–197 (2015).
  Medline CASGoogle Scholar
• 81 Horvath CM, Williams MA, Lamb RA. Eukaryotic coupled translation of tandem cistrons: identification of the influenza B virus BM2 polypeptide. EMBO J. 9(8), 2639–2647 (1990).
  Medline CASGoogle Scholar
• 82 Hatta M, Kohlmeier CK, Hatta Y, Ozawa M, Kawaoka Y. Region required for protein expression from the stop-start pentanucleotide in the M gene of influenza B virus. J. Virol. 83(11), 5939–5942 (2009).
  Medline CASGoogle Scholar
• 83 Powell ML, Napthine S, Jackson RJ, Brierley I, Brown TD. Characterization of the termination–reinitiation strategy employed in the expression of influenza B virus BM2 protein. RNA 14(11), 2394–2406 (2008).
  Medline CASGoogle Scholar
• 84 Powell ML, Leigh KE, Poyry TA, Jackson RJ, Brown TD, Brierley I. Further characterisation of the translational termination–reinitiation signal of the influenza B virus segment 7 RNA. PloS ONE 6(2), e16822 (2011).
  Medline CASGoogle Scholar
• 85 Stevens MP, Barclay WS. The N-terminal extension of the influenza B virus nucleoprotein is not required for nuclear accumulation or the expression and replication of a model RNA. J. Virol. 72(6), 5307–5312 (1998).
  Medline CASGoogle Scholar
• 86 Ng AK, Lam MK, Zhang H et al. Structural basis for RNA binding and homo-oligomer formation by influenza B virus nucleoprotein. J. Virol. 86(12), 6758–6767 (2012).
  Medline CASGoogle Scholar
• 87 Shen YF, Chen YH, Chu SY et al. E339. R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors. Proc. Natl Acad. Sci. USA 108(40), 16515–16520 (2011).
  Medline CASGoogle Scholar
• 88 Wanitchang A, Narkpuk J, Jongkaewwattana A. Nuclear import of influenza B virus nucleoprotein: involvement of an N-terminal nuclear localization signal and a cleavage-protection motif. Virology 443(1), 59–68 (2013).
  Medline CASGoogle Scholar
• 89 Sherry L, Smith M, Davidson S, Jackson D. The N terminus of the influenza B virus nucleoprotein is essential for virus viability, nuclear localization, and optimal transcription and replication of the viral genome. J. Virol. 88(21), 12326–12338 (2014).
  MedlineGoogle Scholar
• 90 Reich S, Guilligay D, Pflug A et al. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature 516(7531), 361–366 (2014).
  Medline CASGoogle Scholar
• 91 Deng Q, Wang D, Xiang X et al. Nuclear localization of influenza B polymerase proteins and their binary complexes. Virus Res. 156(1–2), 49–53 (2011).
  Medline CASGoogle Scholar
• 92 Wakai C, Iwama M, Mizumoto K, Nagata K. Recognition of cap structure by influenza B virus RNA polymerase is less dependent on the methyl residue than recognition by influenza A virus polymerase. J. Virol. 85(15), 7504–7512 (2011).
  Medline CASGoogle Scholar
• 93 Liu Y, Yang Y, Fan J, He R, Luo M, Zheng X. The crystal structure of the PB2 cap-binding domain of influenza B virus reveals a novel cap recognition mechanism. J. Biol. Chem. 290(14), 9141–9149 (2015).
  Medline CASGoogle Scholar
• 94 Cauldwell AV, Long JS, Moncorge O, Barclay WS. Viral determinants of influenza A virus host range. J. Gen. Virol. 95(Pt 6), 1193–1210 (2014).
  Medline CASGoogle Scholar
• 95 Dauber B, Heins G, Wolff T. The influenza B virus nonstructural NS1 protein is essential for efficient viral growth and antagonizes beta interferon induction. J. Virol. 78(4), 1865–1872 (2004).
  Medline CASGoogle Scholar
• 96 Hai R, Martinez-Sobrido L, Fraser KA, Ayllon J, Garcia-Sastre A, Palese P. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J. Virol. 82(21), 10580–10590 (2008).
  Medline CASGoogle Scholar
• 97 Schneider J, Dauber B, Melen K, Julkunen I, Wolff T. Analysis of influenza B Virus NS1 protein trafficking reveals a novel interaction with nuclear speckle domains. J. Virol. 83(2), 701–711 (2009).
  Medline CASGoogle Scholar
• 98 Noah DL, Twu KY, Krug RM. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3′ end processing of cellular pre-mRNAS. Virology 307(2), 386–395 (2003).
  Medline CASGoogle Scholar
• 99 Donelan NR, Dauber B, Wang X, Basler CF, Wolff T, Garcia-Sastre A. The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation. J. Virol. 78(21), 11574–11582 (2004).
  Medline CASGoogle Scholar
• 100 Dauber B, Schneider J, Wolff T. Double-stranded RNA binding of influenza B virus nonstructural NS1 protein inhibits protein kinase R but is not essential to antagonize production of alpha/beta interferon. J. Virol. 80(23), 11667–11677 (2006).
  Medline CASGoogle Scholar
• 101 Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat. Rev. Immunol. 14(5), 315–328 (2014).
  Medline CASGoogle Scholar
• 102 Yuan W, Krug RM. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 20(3), 362–371 (2001).
  Medline CASGoogle Scholar
• 103 Sridharan H, Zhao C, Krug RM. Species specificity of the NS1 protein of influenza B virus: NS1 binds only human and non-human primate ubiquitin-like ISG15 proteins. J. Biol. Chem. 285(11), 7852–7856 (2010).
  Medline CASGoogle Scholar
• 104 Paragas J, Talon J, O’Neill RE, Anderson DK, Garcia-Sastre A, Palese P. Influenza B and C virus NEP (NS2) proteins possess nuclear export activities. J. Virol. 75(16), 7375–7383 (2001).
  Medline CASGoogle Scholar
• 105 Imai M, Watanabe S, Odagiri T. Influenza B virus NS2, a nuclear export protein, directly associates with the viral ribonucleoprotein complex. Arch. Virol. 148(10), 1873–1884 (2003).
  Medline CASGoogle Scholar
• 106 Barclay WS, Palese P. Influenza B viruses with site-specific mutations introduced into the HA gene. J. Virol. 69(2), 1275–1279 (1995).
  Medline CASGoogle Scholar
• 107 Zhou B, Lin X, Wang W et al. Universal influenza B virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics. J. Clin. Microb. 52(5), 1330–1337 (2014).
  MedlineGoogle Scholar
• 108 Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G. Rescue of influenza B virus from eight plasmids. Proc. Natl Acad. Sci. USA 99(17), 11411–11416 (2002).
  Medline CASGoogle Scholar
• 109 Jackson D, Cadman A, Zurcher T, Barclay WS. A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. J. Virol. 76(22), 11744–11747 (2002).
  Medline CASGoogle Scholar
• 110 Baker SF, Nogales A, Finch C et al. Influenza A and B virus intertypic reassortment through compatible viral packaging signals. J. Virol. 88(18), 10778–10791 (2014).
  MedlineGoogle Scholar
• 111 Loo YM, Fornek J, Crochet N et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82(1), 335–345 (2008).
  Medline CASGoogle Scholar
• 112 Dauber B, Martinez-Sobrido L, Schneider J et al. Influenza B virus ribonucleoprotein is a potent activator of the antiviral kinase PKR. PLoS Pathog. 5(6), e1000473 (2009).
  MedlineGoogle Scholar
• 113 Kim MJ, Latham AG, Krug RM. Human influenza viruses activate an interferon-independent transcription of cellular antiviral genes: outcome with influenza A virus is unique. Proc. Natl Acad. Sci. USA 99(15), 10096–10101 (2002).
  Medline CASGoogle Scholar
• 114 Osterlund P, Strengell M, Sarin LP et al. Incoming influenza A virus evades early host recognition, while influenza B virus induces interferon expression directly upon entry. J. Virol. 86(20), 11183–11193 (2012).
  Medline CASGoogle Scholar
• 115 Veckman V, Osterlund P, Fagerlund R, Melen K, Matikainen S, Julkunen I. TNF-alpha and IFN-alpha enhance influenza-A-virus-induced chemokine gene expression in human A549 lung epithelial cells. Virology 345(1), 96–104 (2006).
  Medline CASGoogle Scholar
• 116 Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat. Immunol. 11(5), 404–410 (2010).
  Medline CASGoogle Scholar
• 117 Ponniah S, Doherty PC, Eichelberger M. Selective response of gamma delta T-cell hybridomas to orthomyxovirus-infected cells. J. Virol. 70(1), 17–22 (1996).
  Medline CASGoogle Scholar
• 118 Nunes B, Pechirra P, Coelho A, Ribeiro C, Arraiolos A, Rebelo-de-Andrade H. Heterogeneous selective pressure acting on influenza B Victoria- and Yamagata-like hemagglutinins. J. Mol. Evol. 67(4), 427–435 (2008).
  Medline CASGoogle Scholar
• 119 Wohlbold TJ, Nachbagauer R, Xu H et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio 6(2), e02556 (2015).
  MedlineGoogle Scholar
• 120 Levandowski RA, Gross PA, Weksler M, Staton E, Williams MS, Bonelli J. Cross-reactive antibodies induced by a monovalent influenza B virus vaccine. J. Clin. Microb. 29(7), 1530–1532 (1991).
  Medline CASGoogle Scholar
• 121 Janjua NZ, Skowronski DM, De Serres G et al. Estimates of influenza vaccine effectiveness for 2007–2008 from Canada’s sentinel surveillance system: cross-protection against major and minor variants. J. Infect. Dis. 205(12), 1858–1868 (2012).
  Medline CASGoogle Scholar
• 122 Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics 118(3), e579–e585 (2006).
  MedlineGoogle Scholar
• 123 Walter EB, Neuzil KM, Zhu Y et al. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Pediatrics 118(3), e570–e578 (2006).
  MedlineGoogle Scholar
• 124 Ohmit SE, Thompson MG, Petrie JG et al. Influenza vaccine effectiveness in the 2011–2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin. Infect. Dis. 58(3), 319–327 (2014).
  MedlineGoogle Scholar
• 125 Skowronski DM, Hottes TS, De Serres G et al. Influenza Beta/Victoria antigen induces strong recall of Beta/Yamagata but lower Beta/Victoria response in children primed with two doses of Beta/Yamagata. Pediatr. Infect. Dis. J. 30(10), 833–839 (2011).
  MedlineGoogle Scholar
• 126 Dreyfus C, Laursen NS, Kwaks T et al. Highly conserved protective epitopes on influenza B viruses. Science 337(6100), 1343–1348 (2012).
  Medline CASGoogle Scholar
• 127 Yasugi M, Kubota-Koketsu R, Yamashita A et al. Human monoclonal antibodies broadly neutralizing against influenza B virus. PLoS Pathog. 9(2), e1003150 (2013).
  Medline CASGoogle Scholar
• 128 Gravel C, Li C, Wang J et al. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 28(36), 5774–5784 (2010).
  Medline CASGoogle Scholar
• 129 Doyle TM, Li C, Bucher DJ et al. A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. Biochem. Biophys. Res. Commun. 441(1), 226–229 (2013).
  Medline CASGoogle Scholar
• 130 McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309(1), 13–17 (1983).
  Medline CASGoogle Scholar
• 131 Gras S, Kedzierski L, Valkenburg SA et al. Cross-reactive CD8⁺ T-cell immunity between the pandemic H1N1–2009 and H1N1–1918 influenza A viruses. Proc. Natl Acad. Sci. USA 107(28), 12599–12604 (2010).
  Medline CASGoogle Scholar
• 132 Sridhar S, Begom S, Bermingham A et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19(10), 1305–1312 (2013).
  Medline CASGoogle Scholar
• 133 Quinones-Parra S, Grant E, Loh L et al. Preexisting CD8⁺ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc. Natl Acad. Sci. USA 111(3), 1049–1054 (2014).
  Medline CASGoogle Scholar
• 134 Wang Z, Wan Y, Qiu C et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(⁺) T cells. Nat. Commun. 6, 6833 (2015).
  Medline CASGoogle Scholar
• 135 Hillaire ML, van Trierum SE, Kreijtz JH et al. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J. Gen. Virol. 92(Pt 10), 2339–2349 (2011).
  Medline CASGoogle Scholar
• 136 Epstein SL, Lo CY, Misplon JA, Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J. Immunol. 160(1), 322–327 (1998).
  Medline CASGoogle Scholar
• 137 Robbins PA, Lettice LA, Rota P et al. Comparison between two peptide epitopes presented to cytotoxic T lymphocytes by HLA-A2. Evidence for discrete locations within HLA-A2. J. Immunol. 143(4089), 103 (1989).
  MedlineGoogle Scholar
• 138 Robbins PA, Rota PA, Shapiro SZ. A broad cytotoxic T lymphocyte response to influenza type B virus presented by multiple HLA molecules. Int. Immunol. 9(6), 815–823 (1997).
  Medline CASGoogle Scholar
• 139 van de Sandt CE, Dou Y, Vogelzang-van Trierum SE et al. Influenza B virus-specific CD8⁺ T lymphocytes strongly cross-react with viruses of the opposing influenza B lineage. J. Gen. Virol. 96(8), 2061–2073 (2015).
  Medline CASGoogle Scholar
• 140 Boon AC, De Mutsert G, Fouchier RA, Sintnicolaas K, Osterhaus AD, Rimmelzwaan GF. Preferential HLA usage in the influenza virus-specific CTL response. J. Immunol. 172(7), 4435–4443 (2004).
  Medline CASGoogle Scholar
• 141 Terajima M, Babon JA, Co MD, Ennis FA. Cross-reactive human B cell and T cell epitopes between influenza A and B viruses. Virol. J. 10, 244 (2013).
  Medline CASGoogle Scholar
• 142 Epstein SL, Lo CY, Misplon JA et al. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J. Immunol. 158(3), 1222–1230 (1997).
  Medline CASGoogle Scholar
• 143 Benton KA, Misplon JA, Lo CY, Brutkiewicz RR, Prasad SA, Epstein SL. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or T cells. J. Immunol. 166(12), 7437–7445 (2001).
  Medline CASGoogle Scholar
• 144 Beran J, Peeters M, Dewe W, Raupachova J, Hobzova L, Devaster JM. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect. Dis. 13, 224 (2013).
  Medline CASGoogle Scholar
• 145 Graaf H, Faust SN. Fluarix quadrivalent vaccine for influenza. Exp. Rev. Vaccines 14(8), 1055–1063 (2015).
  MedlineGoogle Scholar
• 146 Tinoco JC, Pavia-Ruz N, Cruz-Valdez A et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged >/=18 years: a Phase III, randomized trial. Vaccine 32(13), 1480–1487 (2014).
  Medline CASGoogle Scholar
• 147 Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R, Cold-adapted TIVSG. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr. Infect. Dis. J. 22(1), 28–34 (2003).
  MedlineGoogle Scholar
• 148 Huber VC, Kleimeyer LH, McCullers JA. Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine 26(42), 5381–5388 (2008).
  Medline CASGoogle Scholar
• 149 Lee MS, Mahmood K, Adhikary L et al. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 23(9), 852–856 (2004).
  MedlineGoogle Scholar
• 150 Le J, Orff EJ, Fulvini AA et al. Development of high yield reassortants for influenza type B viruses and analysis of their gene compositions. Vaccine 33(7), 879–884 (2015).
  MedlineGoogle Scholar
• 151 Burnham AJ, Armstrong J, Lowen AC, Webster RG, Govorkova EA. Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium. J. Virol. 89(8), 4575–4587 (2015).
  Medline CASGoogle Scholar
• 152 Burnham AJ, Baranovich T, Marathe BM, Armstrong J, Webster RG, Govorkova EA. Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob. Agents Chemother. 58(5), 2718–2730 (2014).
  MedlineGoogle Scholar
• 153 Farrukee R, Leang SK, Butler J et al. Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility. J. Antimicrob. Chemother. 70(7), 2004–2012 (2015).
  Medline CASGoogle Scholar